SCRMP-mediated SUMOylation of CSNK2B facilitates DNA damage repair to promote cisplatin resistance in small cell lung cancer.

SCRMP-mediated SUMOylation of CSNK2B enhances DNA repair and is linked to platinum resistance in small cell lung cancer.

• Why it matters: Understanding the molecular basis of platinum resistance in SCLC is crucial because it leads to treatment failure and limited therapeutic options.
• What they did: Researchers used multiomic analysis of cisplatin-resistant tissues and cells, identifying SCRMP, a 128-amino acid protein upregulated in resistant SCLC, and demonstrated its role via CRISPR-Cas9 knockout and mechanistic studies.
• The result: Elevated SCRMP correlates with poor survival and resistance, and its knockout restores cisplatin sensitivity, suggesting SCRMP as a potential target to overcome resistance in SCLC.